Arbor Vita

Arbor Vita is a private, commercial-stage diagnostics company founded in 1999. It has built a unique technology foundation around PDZ domain biology and monoclonal antibodies to develop rapid, actionable diagnostic tests for global health challenges, with a focus on infectious disease pandemics and cervical cancer screening. The company has successfully brought FDA-cleared products to market, operates a CLIA-certified testing lab for COVID-19, and collaborates with entities like the U.S. Navy and Yale University. Its strategy targets both advanced and low-resource healthcare settings to improve early detection and health outcomes.

Proprietary PDZ proteomics platform for target discovery, combined with a proprietary monoclonal antibody (mAb) library for development of rapid diagnostic tests. This enables the creation of sensitive, point-of-care tests for specific protein markers in infectious diseases and cancers.

In rapid influenza diagnostics, Arbor Vita competes with other FDA-cleared test manufacturers and broader PCR-based lab services. In cervical cancer screening, it competes directly with established Pap smear cytology, HPV DNA tests (like Roche Cobas, Qiagen), and newer molecular assays, differentiating itself through a protein-based, point-of-care format designed for low-resource settings.